Prognostic significance of neutropenia during adjuvant concurrent chemoradiotherapy in early cervical cancer.
10.3802/jgo.2009.20.3.146
- Author:
Yun Hwan KIM
1
;
Hyun Hoon CHUNG
;
Jae Weon KIM
;
Noh Hyun PARK
;
Yong Sang SONG
;
Soon Beom KANG
Author Information
1. Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea. kjwksh@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Uterine cervical cancer;
Chemoradiotherapy;
Neutropenia;
Survival
- MeSH:
Carcinoma, Squamous Cell;
Cervix Uteri;
Chemoradiotherapy;
Disease-Free Survival;
Female;
Follow-Up Studies;
Humans;
Lymph Node Excision;
Multivariate Analysis;
Neoplasm Metastasis;
Neutropenia;
Neutrophils;
Paclitaxel;
Recurrence;
Retrospective Studies;
Uterine Cervical Neoplasms
- From:Journal of Gynecologic Oncology
2009;20(3):146-150
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate the prognostic significance of adjuvant concurrent chemoradiotherapy-induced neutropenia with survival in patients with squamous cell carcinoma of the uterine cervix. METHODS: Data from 107 patients with stage IB-IIB cervical cancer were retrospectively analyzed. The median follow-up was 37.5 (4.2-72.7) months. All patients had received radical surgery, including pelvic lymphadenectomy, followed by paclitaxel plus carboplatin-based concurrent chemoradiotherapy. Relative neutropenia, defined as an absolute neutrophil count <1,000/mm3 at the concurrent chemoradiotherapy cycle nadir, correlated to the pathologic findings and survival outcomes. RESULTS: Sixty-six patients experienced neutropenia at least once during concurrent chemoradiotherapy, and demonstrated marginal improvement in disease-free survival (p=0.055), although not in overall survival. By subgroup analyses, the gain of disease free survival mainly originated from the node metastasis subgroup (p=0.033). Treatment-induced neutropenia proved to be the only significant independent factor for recurrence in cervical cancer (p=0.042) by multivariate analysis. CONCLUSION: Concurrent chemoradiotherapy-induced neutropenia may be a prognostic factor of recurrence in patients with cervical cancer. Individualized dose titration of the tolerable myelosuppression might be beneficial.
